158 related articles for article (PubMed ID: 11426843)
1. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
Fride E; Ginzburg Y; Breuer A; Bisogno T; Di Marzo V; Mechoulam R
Eur J Pharmacol; 2001 May; 419(2-3):207-14. PubMed ID: 11426843
[TBL] [Abstract][Full Text] [Related]
2. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R
Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.
Mallet PE; Beninger RJ
Psychopharmacology (Berl); 1998 Nov; 140(1):11-9. PubMed ID: 9862397
[TBL] [Abstract][Full Text] [Related]
4. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
[TBL] [Abstract][Full Text] [Related]
5. Mesenteric vasodilation mediated by endothelial anandamide receptors.
Wagner JA; Varga K; Járai Z; Kunos G
Hypertension; 1999 Jan; 33(1 Pt 2):429-34. PubMed ID: 9931142
[TBL] [Abstract][Full Text] [Related]
6. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716.
Higgs S; Williams CM; Kirkham TC
Psychopharmacology (Berl); 2003 Feb; 165(4):370-7. PubMed ID: 12447606
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
11. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.
Wallace MJ; Martin BR; DeLorenzo RJ
Eur J Pharmacol; 2002 Oct; 452(3):295-301. PubMed ID: 12359270
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
14. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
[TBL] [Abstract][Full Text] [Related]
16. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
[TBL] [Abstract][Full Text] [Related]
17. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
Costa B; Colleoni M
Eur J Pharmacol; 2000 Apr; 395(1):1-7. PubMed ID: 10781666
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
[TBL] [Abstract][Full Text] [Related]
20. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]